3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
10
Phase 1
5
Phase 1/2
4
Phase 3
3
Phase 2/3
2
Status
Recruiting
1
Completed
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
1
Breast
1
Conditions
HER2-positive Breast Cancer
1
Adenocarcinoma Of Esophagus
1
Interventions
Cisplatin
29
Carboplatin
28
Gemcitabine
27
Paclitaxel
26
pembrolizumab
24
Capecitabine
16
Pemetrexed
15
Bevacizumab
15
Docetaxel
14
Oxaliplatin
13
Fluorouracil
12
Drug Therapy
12
Nivolumab
10
130-nm albumin-bound paclitaxel
9
Trastuzumab
8
anlotinib
7
Injections
7
Rituximab
6
venetoclax
5
atezolizumab
5
Temozolomide
5
Leucovorin
5
Ipilimumab
5
Lenalidomide
4
Irinotecan
4
Interferon alpha-2
4
Folfox protocol
4
Dexamethasone
4
Azacitidine
4
Albumin-Bound Paclitaxel
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 2/3
×
INDUSTRY
×
tucatinib
×
Clear all
NCT07413939
2026-05-11
BREnnA
Hoffmann-La Roche
Phase 2/3
Recruiting
650 enrolled
NCT04499924
2025-01-22
MOUNTAINEER-02
Seagen Inc.
Phase 2/3
Completed
17 enrolled
23 charts